Search research articles
Contact Us
Filters
Showing results (291-300 of 303) with videos related to
Page
of 31
Sort By:
Cancer Research and Treatment
|
September 5, 2018
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
April 25, 2023
Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8<sup>+</sup> T Cells
Se-Hoon Lee, Yeongmin Kim, Bu-Nam Jeon, et al.
British Journal of Cancer
|
September 23, 2020
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
Hye Ryun Kim, Han Na Kang, Mi Ran Yun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2015
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04
Jin Seok Ahn, Yong Chan Ahn, Joo-Hang Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung-Bae Kim, et al.
International Journal of Oncology
|
November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review
William K Oh, David McDermott, Camillo Porta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2023
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With <i>EGFR</i>- or <i>ALK</i>-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)
Sehhoon Park, Tae Min Kim, Ji-Youn Han, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 27, 2021
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
Byoung Chul Cho, Ji-Youn Han, Sang-We Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
Han Sang Kim, Hyeong Ju Kwon, Inkyung Jung, et al.
Oncotarget
|
October 14, 2015
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
Hyo Song Kim, Sung-Moo Kim, Hyunki Kim, et al.
Page
of 31
Search research articles
Search
Showing results (291-300 of 303) with videos related to
Sort By:
Page
of 31
Cancer Research and Treatment
|
September 5, 2018
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
April 25, 2023
Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8<sup>+</sup> T Cells
Se-Hoon Lee, Yeongmin Kim, Bu-Nam Jeon, et al.
British Journal of Cancer
|
September 23, 2020
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
Hye Ryun Kim, Han Na Kang, Mi Ran Yun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2015
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04
Jin Seok Ahn, Yong Chan Ahn, Joo-Hang Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung-Bae Kim, et al.
International Journal of Oncology
|
November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review
William K Oh, David McDermott, Camillo Porta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2023
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With <i>EGFR</i>- or <i>ALK</i>-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)
Sehhoon Park, Tae Min Kim, Ji-Youn Han, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 27, 2021
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
Byoung Chul Cho, Ji-Youn Han, Sang-We Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
Han Sang Kim, Hyeong Ju Kwon, Inkyung Jung, et al.
Oncotarget
|
October 14, 2015
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
Hyo Song Kim, Sung-Moo Kim, Hyunki Kim, et al.
Page
of 31